Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 511

1.

Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration.

Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA.

J Virol. 2008 Jul;82(13):6458-69. doi: 10.1128/JVI.00068-08. Epub 2008 Apr 30.

PMID:
18448544
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

PMID:
21864626
[PubMed - indexed for MEDLINE]
3.
4.

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team.

PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.

PMID:
20126394
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.

Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL.

J Immunol. 2002 Jan 15;168(2):562-8.

PMID:
11777947
[PubMed - indexed for MEDLINE]
Free Article
6.

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.

AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93.

PMID:
8744579
[PubMed - indexed for MEDLINE]
7.

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Bridge SH, Sharpe SA, Dennis MJ, Dowall SD, Getty B, Anson DS, Skinner MA, Stewart JP, Blanchard TJ.

Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429.

PMID:
21899739
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.

Burgers WA, Chege GK, Müller TL, van Harmelen JH, Khoury G, Shephard EG, Gray CM, Williamson C, Williamson AL.

J Gen Virol. 2009 Feb;90(Pt 2):468-80. doi: 10.1099/vir.0.004614-0.

PMID:
19141458
[PubMed - indexed for MEDLINE]
Free Article
10.

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.

Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R.

Virology. 2006 Mar 1;346(1):151-68. Epub 2005 Dec 2.

PMID:
16325880
[PubMed - indexed for MEDLINE]
Free Article
11.

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.

Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R; HIV Network for Prevention Trials.

J Infect Dis. 2003 Mar 15;187(6):887-95. Epub 2003 Mar 6.

PMID:
12660934
[PubMed - indexed for MEDLINE]
Free Article
12.

Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.

Sailaja G, Husain S, Nayak BP, Jabbar AM.

J Immunol. 2003 Mar 1;170(5):2496-507.

PMID:
12594275
[PubMed - indexed for MEDLINE]
Free Article
13.

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.

Virology. 2006 Jun 20;350(1):34-47. Epub 2006 Apr 17.

PMID:
16616287
[PubMed - indexed for MEDLINE]
Free Article
14.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

PMID:
16227256
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.

Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, Herndon JG, Wyatt LS, Montefiori D, Moss B, McClure HM, Robinson HL.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47.

PMID:
15650426
[PubMed - indexed for MEDLINE]
16.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

PMID:
22146759
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL.

AIDS Res Hum Retroviruses. 2008 Feb;24(2):207-17. doi: 10.1089/aid.2007.0206.

PMID:
18240963
[PubMed - indexed for MEDLINE]
18.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

PMID:
21857901
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.

Bower JF, Green TD, Ross TM.

Virology. 2004 Oct 25;328(2):292-300.

PMID:
15464849
[PubMed - indexed for MEDLINE]
Free Article
20.

A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B.

Mol Ther. 2007 Sep;15(9):1724-33. Epub 2007 Jun 19.

PMID:
17579577
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk